vs
4D Molecular Therapeutics, Inc.（FDMT）与STEM, INC.（STEM）财务数据对比。点击上方公司名可切换其他公司
4D Molecular Therapeutics, Inc.的季度营收约是STEM, INC.的1.8倍（$85.1M vs $47.1M），4D Molecular Therapeutics, Inc.净利率更高（22.8% vs -33.9%，领先56.7%），4D Molecular Therapeutics, Inc.同比增速更快（8508900.0% vs -15.6%），过去两年4D Molecular Therapeutics, Inc.的营收复合增速更高（5412.6% vs 36.1%）
4D Molecular Therapeutics是一家临床阶段生物技术企业，专注于研发靶向腺相关病毒（AAV）基因疗法，核心在研产品覆盖眼科、心脏病学、肺部疾病领域，为全球存在未满足医疗需求的罕见病和常见病患者提供新型治疗方案。
该公司是一家公开上市的生物制药企业，总部位于加利福尼亚州纽瓦克，专注研发纯化人类神经干细胞，旨在治疗中枢神经系统疾病与瘫痪，其所研发的神经干细胞可分化为中枢神经系统的神经元、星形胶质细胞与少突胶质细胞这三大主要细胞类型。
FDMT vs STEM — 直观对比
营收规模更大
FDMT
是对方的1.8倍
$47.1M
营收增速更快
FDMT
高出8508915.6%
-15.6%
净利率更高
FDMT
高出56.7%
-33.9%
两年增速更快
FDMT
近两年复合增速
36.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $85.1M | $47.1M |
| 净利润 | $19.4M | $-16.0M |
| 毛利率 | — | 48.9% |
| 营业利润率 | 17.3% | -17.7% |
| 净利率 | 22.8% | -33.9% |
| 营收同比 | 8508900.0% | -15.6% |
| 净利润同比 | 139.1% | 68.8% |
| 每股收益（稀释后） | $0.43 | $-4.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FDMTSTEM
| Q4 25 | $85.1M | $47.1M | ||
| Q3 25 | $90.0K | $38.2M | ||
| Q2 25 | $15.0K | $38.4M | ||
| Q1 25 | $14.0K | $32.5M | ||
| Q4 24 | $1.0K | $55.8M | ||
| Q3 24 | $3.0K | $29.3M | ||
| Q2 24 | $5.0K | $34.0M | ||
| Q1 24 | $28.0K | $25.5M |
净利润FDMTSTEM
| Q4 25 | $19.4M | $-16.0M | ||
| Q3 25 | $-56.9M | $-23.8M | ||
| Q2 25 | $-54.7M | $202.5M | ||
| Q1 25 | $-48.0M | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | $-43.8M | $-148.3M | ||
| Q2 24 | $-35.0M | $-582.3M | ||
| Q1 24 | $-32.4M | $-72.3M |
毛利率FDMTSTEM
| Q4 25 | — | 48.9% | ||
| Q3 25 | — | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 32.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | -95.0% |
营业利润率FDMTSTEM
| Q4 25 | 17.3% | -17.7% | ||
| Q3 25 | -67983.3% | -33.6% | ||
| Q2 25 | -396373.3% | -34.8% | ||
| Q1 25 | -383007.1% | -65.0% | ||
| Q4 24 | — | -84.4% | ||
| Q3 24 | -1704400.0% | -493.2% | ||
| Q2 24 | -849120.0% | -1705.5% | ||
| Q1 24 | -136200.0% | -267.0% |
净利率FDMTSTEM
| Q4 25 | 22.8% | -33.9% | ||
| Q3 25 | -63195.6% | -62.2% | ||
| Q2 25 | -364386.7% | 527.8% | ||
| Q1 25 | -342657.1% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | -1461433.3% | -506.3% | ||
| Q2 24 | -699060.0% | -1712.6% | ||
| Q1 24 | -115717.9% | -283.9% |
每股收益（稀释后）FDMTSTEM
| Q4 25 | $0.43 | $-4.40 | ||
| Q3 25 | $-1.01 | $-2.84 | ||
| Q2 25 | $-0.98 | $-1.79 | ||
| Q1 25 | $-0.86 | $-0.15 | ||
| Q4 24 | — | $-15.29 | ||
| Q3 24 | $-0.79 | $-18.24 | ||
| Q2 24 | $-0.63 | $-71.81 | ||
| Q1 24 | $-0.66 | $-0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $402.7M | $48.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $505.7M | $-249.4M |
| 总资产 | $566.7M | $308.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FDMTSTEM
| Q4 25 | $402.7M | $48.9M | ||
| Q3 25 | $305.1M | $43.1M | ||
| Q2 25 | $293.2M | $40.8M | ||
| Q1 25 | $321.4M | $58.6M | ||
| Q4 24 | $424.9M | $56.3M | ||
| Q3 24 | $501.9M | $75.4M | ||
| Q2 24 | $541.9M | $89.6M | ||
| Q1 24 | $525.9M | $112.8M |
股东权益FDMTSTEM
| Q4 25 | $505.7M | $-249.4M | ||
| Q3 25 | $369.0M | $-235.7M | ||
| Q2 25 | $420.9M | $-214.1M | ||
| Q1 25 | $469.7M | $-417.5M | ||
| Q4 24 | $510.6M | $-398.4M | ||
| Q3 24 | $552.9M | $-344.1M | ||
| Q2 24 | $588.3M | $-203.2M | ||
| Q1 24 | $600.6M | $371.6M |
总资产FDMTSTEM
| Q4 25 | $566.7M | $308.9M | ||
| Q3 25 | $424.0M | $362.6M | ||
| Q2 25 | $473.6M | $379.2M | ||
| Q1 25 | $515.7M | $405.1M | ||
| Q4 24 | $560.4M | $437.4M | ||
| Q3 24 | $604.0M | $537.8M | ||
| Q2 24 | $620.1M | $691.5M | ||
| Q1 24 | $629.9M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.6M | $8.2M |
| 自由现金流经营现金流 - 资本支出 | $28.5M | — |
| 自由现金流率自由现金流/营收 | 33.5% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | 1.47× | — |
| 过去12个月自由现金流最近4个季度 | $-109.9M | — |
8季度趋势，按日历期对齐
经营现金流FDMTSTEM
| Q4 25 | $28.6M | $8.2M | ||
| Q3 25 | $-46.5M | $11.4M | ||
| Q2 25 | $-43.4M | $-21.3M | ||
| Q1 25 | $-47.8M | $8.5M | ||
| Q4 24 | $-134.6M | $-14.7M | ||
| Q3 24 | $-29.4M | $-9.4M | ||
| Q2 24 | $-30.2M | $-11.9M | ||
| Q1 24 | $-29.1M | $-621.0K |
自由现金流FDMTSTEM
| Q4 25 | $28.5M | — | ||
| Q3 25 | $-46.6M | — | ||
| Q2 25 | $-43.4M | — | ||
| Q1 25 | $-48.4M | — | ||
| Q4 24 | $-138.4M | — | ||
| Q3 24 | $-31.2M | — | ||
| Q2 24 | $-30.6M | — | ||
| Q1 24 | $-29.8M | — |
自由现金流率FDMTSTEM
| Q4 25 | 33.5% | — | ||
| Q3 25 | -51765.6% | — | ||
| Q2 25 | -289620.0% | — | ||
| Q1 25 | -345635.7% | — | ||
| Q4 24 | -13837100.0% | — | ||
| Q3 24 | -1038966.7% | — | ||
| Q2 24 | -611840.0% | — | ||
| Q1 24 | -106421.4% | — |
资本支出强度FDMTSTEM
| Q4 25 | 0.1% | — | ||
| Q3 25 | 101.1% | — | ||
| Q2 25 | 440.0% | — | ||
| Q1 25 | 4507.1% | — | ||
| Q4 24 | 378600.0% | — | ||
| Q3 24 | 59266.7% | — | ||
| Q2 24 | 6980.0% | — | ||
| Q1 24 | 2535.7% | — |
现金转化率FDMTSTEM
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
